非小细胞肺癌术后表皮生长因子受体-酪氨酸激酶抑制剂辅助治疗研究进展

Advances in EGFR-TKIs as adjuvant therapy in post-surgery of non-small cell lung cancer

非小细胞肺癌约占全部肺癌总数的85%。早期非小细胞肺癌主要治疗手段是外科手术,术后进行辅助化疗有助于提高生存期,但Ⅱ期和ⅢA期患者的总生存仅有4%~15%的临床获益,而其带来的不良反应严重影响患者生活质量,并增加非肿瘤相关性病死率。表皮生长因子受体（epidermal growth factor receptor,EGFR）-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKI）是EGFR基因突变的晚期非小细胞肺癌的重要治疗手段,但能否应用于早、中期肺癌辅助治疗仍有待进一步证实,本文将对EGFR-TKIs应用于非小细胞肺癌术后辅助治疗的相关热点问题进行阐述。

Lung cancer is the most common malignant disease with the highest mortality, among which non-small cell lung cancer （NSCLC） accounts for nearly 85% of all cases. The first-line treatment for NSCLC is surgery, followed by chemotherapy in order to improve overall survival. However, only 4% - 15% patients demonstrate improved treatment benefit, while chemotherapy-related side effects greatly worsen the quality of life and increase non-tumor-related mortality. EGFR-TKIs are important treatment options for late stage NSCLC with EGFR mutations. Whether or not EGFR-TKIs can be used in intermediate stage NSCLC needs further validation. In this article, we review and discuss the topics on EGFR-TKIs as adjuvant therapy in post-surgery of NSCLC.